Clinical Trials | April 30, 2026
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
The Danish biotech company confirmed the global study will begin in the second half of 2026
The Danish biotech company confirmed the global study will begin in the second half of 2026
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The companies aim to expand treatment options for millions living with metabolic disorders
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Subscribe To Our Newsletter & Stay Updated
